Development of Self-Associating SN-38-Conjugated Poly(ethylene oxide)-Poly(ester) Micelles for Colorectal Cancer Therapy.

SN-38 chemotherapy colorectal cancer irinotecan mPEO-b-PBCL mPEO-b-PCCL polymeric micelle

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
29 Oct 2020
Historique:
received: 12 10 2020
revised: 25 10 2020
accepted: 26 10 2020
entrez: 3 11 2020
pubmed: 4 11 2020
medline: 4 11 2020
Statut: epublish

Résumé

The clinical use of 7-ethyl-10-hydroxy-camptothecin (SN-38), which is the active metabolite of irinotecan, has been hampered because of its practical water-insolubility. In this study, we successfully synthesized two self-associating SN-38-polymer drug conjugates to improve the water-solubility of SN-38, while retaining its anticancer activity. The polymeric micellar SN-38 conjugates were composed of either methoxy-poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) conjugated to SN-38 at the PBCL end (mPEO-

Identifiants

pubmed: 33138058
pii: pharmaceutics12111033
doi: 10.3390/pharmaceutics12111033
pmc: PMC7694018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : CIHR
ID : FRN159757
Pays : Canada
Organisme : Alberta Cancer Foundation
ID : 26603

Références

PDA J Pharm Sci Technol. 2009 Nov-Dec;63(6):512-20
pubmed: 20169857
Int J Nanomedicine. 2015 Mar 23;10:2295-311
pubmed: 25848251
J Neurosurg. 2011 Mar;114(3):689-94
pubmed: 20415520
Eur J Pharm Biopharm. 2011 Sep;79(1):181-8
pubmed: 21303693
Acta Pharm Sin B. 2015 Sep;5(5):442-53
pubmed: 26579474
J Nat Med. 2017 Jan;71(1):50-58
pubmed: 27491744
Yao Xue Xue Bao. 2004 Aug;39(8):591-7
pubmed: 15563058
Expert Opin Drug Deliv. 2005 Mar;2(2):311-22
pubmed: 16296756
Colloids Surf B Biointerfaces. 2015 Aug 1;132:161-70
pubmed: 26037706
Adv Drug Deliv Rev. 2001 Mar 23;47(1):113-31
pubmed: 11251249
Clin Cancer Res. 2002 Mar;8(3):641-61
pubmed: 11895891
Cancer Sci. 2009 Apr;100(4):572-9
pubmed: 19462526
Sci Rep. 2016 May 05;6:25518
pubmed: 27145858
Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118688
pubmed: 32087180
Nat Rev Clin Oncol. 2013 Mar;10(3):130-42
pubmed: 23381005
Bioorg Med Chem. 2004 Jul 1;12(13):3657-62
pubmed: 15186850
Nanomedicine. 2010 Jun;6(3):478-85
pubmed: 19836467
Macromol Biosci. 2010 Jun 11;10(6):648-56
pubmed: 20352627
Eur J Pharm Biopharm. 2015 Jun;93:52-79
pubmed: 25813885
J Med Chem. 1987 Oct;30(10):1774-9
pubmed: 3656353
Mol Pharm. 2018 Jun 4;15(6):2316-2326
pubmed: 29688721
Expert Opin Drug Deliv. 2006 Jan;3(1):139-62
pubmed: 16370946
Cancer Res. 2006 Oct 15;66(20):10048-56
pubmed: 17047068
Cancer Chemother Pharmacol. 2018 Dec;82(6):1021-1029
pubmed: 30284603
J Control Release. 2014 Aug 10;187:133-44
pubmed: 24874289
J Control Release. 2011 Mar 30;150(3):318-25
pubmed: 21115079
Cells. 2019 Oct 07;8(10):
pubmed: 31591302
Adv Drug Deliv Rev. 2011 Mar 18;63(3):184-92
pubmed: 20561951
Cancer. 2010 Oct 1;116(19):4597-604
pubmed: 20572031
J Control Release. 2005 Dec 5;109(1-3):169-88
pubmed: 16289422
J Med Chem. 1996 May 10;39(10):1938-40
pubmed: 8642549
Biomaterials. 2013 Nov;34(34):8756-65
pubmed: 23937913
Eur J Pharm Biopharm. 2008 Aug;69(3):923-34
pubmed: 18430550
J Invest Dermatol. 1991 Jul;97(1):80-4
pubmed: 2056195
Int J Pharm. 2011 Mar 15;406(1-2):122-7
pubmed: 21185365
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2729-36
pubmed: 24966994
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Colloids Surf B Biointerfaces. 2015 Feb 1;126:631-48
pubmed: 25591851
J Org Chem. 2012 Jan 6;77(1):713-7
pubmed: 22165912
Cancer Res. 1994 Jul 15;54(14):3723-5
pubmed: 8033091
ACS Omega. 2019 Nov 01;4(20):18867-18879
pubmed: 31737848
Biomacromolecules. 2004 Sep-Oct;5(5):1756-62
pubmed: 15360284
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Sams M A Sadat (SMA)

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Mohammad Reza Vakili (MR)

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Igor M Paiva (IM)

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Michael Weinfeld (M)

Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.
Department of Experimental Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.

Afsaneh Lavasanifar (A)

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Department of Chemical and Material Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.

Classifications MeSH